A meta-analysis of 19 studies involving up to 180,180 individuals showed a 34% reduction of CAD odds ratio among carriers of an ANGPTL3 loss-of function mutation compared to control participants [35]. This evidence concerns the gene ANGPTL3 and coronary artery disorder.